0001209191-20-003949.txt : 20200117
0001209191-20-003949.hdr.sgml : 20200117
20200117161011
ACCESSION NUMBER: 0001209191-20-003949
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200115
FILED AS OF DATE: 20200117
DATE AS OF CHANGE: 20200117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Morl Christopher John
CENTRAL INDEX KEY: 0001716821
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 20533668
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC
STREET 2: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-15
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001716821
Morl Christopher John
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM
MA
02451
0
1
0
0
Chief Business Officer
Common Stock
2020-01-15
4
M
0
12023
3.95
A
12023
D
Common Stock
2020-01-15
4
S
0
12023
65.2311
D
0
D
Common Stock
2020-01-16
4
M
0
3011
3.95
A
3011
D
Common Stock
2020-01-16
4
S
0
3011
65.4041
D
0
D
Stock Option (Right to Buy)
3.95
2020-01-15
4
M
0
12023
0.00
D
2026-10-20
Common Stock
12023
153355
D
Stock Option (Right to Buy)
3.95
2020-01-16
4
M
0
3011
0.00
D
2026-10-20
Common Stock
3011
150344
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.45, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.005 to $66.03, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal quarterly installments at the end of each quarter following the vesting commencement date of October 3, 2016, subject to continued service through such dates.
/s/ Thomas P. Kelly, Attorney-in-Fact
2020-01-17